Friday, May 15, 2009

Amgen Highlights Data to Be Presented at ASCO

New Vectibix(R) (Panitumumab) Combination Chemotherapy Data

New Data Reinforce Importance of Infection Prevention in Chemotherapy Patients

Oncology Pipeline Continues to Advance With New Data in Multiple Tumor Types

THOUSAND OAKS, Calif. – May 15 – Amgen (Nasdaq: AMGN) today announced it will present new data from the Company’s oncology portfolio of approved and investigational cancer products at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla. fromMay 29 to June 2, 2009. Data will be presented from several programs, including Vectibix(R) (panitumumab), Neulasta(R) (pegfilgrastim), Aranesp(R) (darbepoetin alfa), denosumab, conatumumab (AMG 655), dulanermin (rhApo2L/TRAIL) and AMG 479.

Posted in Press Releases, Product News, Pipeline News